Clinical trials: Blood Plasma Therapy
Waldenström Macroglobulinemia (WM)
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
This study is a prospective phase II clinical trial designed to evaluate the deep response rate of the ZBR regimen (zanubrutinib combined with reduced-dose bendamustine and CD20 Monoclonal Antibody ) in treatment-naïve…
- Trial name
- ZBR in WM (NCT07259122)
- Testing
- Zaunbrutinib, Bendamustine and Rituximab for induction therapy, Zanubrutinib mono therapy for maintenance treatment
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
This is a multicenter, single arm, open-label, Phase 2 study in mutiple myeloma with newly diagnosed and treatment-naïve participants for whom high-dose therapy and autologous stem cell transplantation is part of the intended…
- Trial name
- TAURUS (NCT06189833)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 31 sites in Austria, Germany and 3 more
- Volunteers
- 200 people
- Sponsor
- Stichting European Myeloma Network
Thrombotic Microangiopathies
Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura
Immune thrombotic thrombocytopenic purpura (iTTP) is caused by a severe, autoantibody-mediated deficiency of ADAMTS13 leading to an accumulation of ultra-large von Willebrand factor multimers in plasma and finally to microthrombi…
- Trial name
- PEX-FREE (NCT06291025)
- Testing
- PEX-FREE
- Where
- 30 sites in France, Martinique and 1 more
- Volunteers
- 131 people
- Sponsor
- University Hospital, Rouen
Vitiligo
Platelet-rich Plasma Intradermal Injection Combined With 308 nm Excimer Light for Treating Stable Acral Vitiligo
The goal of this clinical trial is to learn if platelet-rich plasma (PRP) works to treat acral stable vitiligo in adults. It will also learn about the safety of platelet-rich plasma.
- Trial name
- NCT06394349
- Testing
- PRP+308nm, NS+308nm
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yijian Zhu
Relapsed Refractory Multiple Myeloma (RRMM)
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of BCMA/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with…
- Trial name
- CM336-001 (NCT07407010)
- Testing
- CM336 (BCMA/CD3 bispecific antibody)
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the highest dose of lenalidomide and RAD001 that can be given without causing too many serious side effects.
- Trial name
- NCT00729638
- Testing
- RAD001, lenalidomide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Osteoarthritis, Knee
The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis
This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ and RegenoGel™ to treat knee pain and effect on subject's activity and quality of life.
- Trial name
- NCT03479749
- Testing
- RegenoGel-OSP, RegenoGel
- Where
- 5 sites in Israel
- Volunteers
- 67 people
- Sponsor
- ProCore Ltd.
Myeloma
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients…
- Trial name
- IMPACT (NCT07878208)
- Where
- 7 sites in Denmark, Norway
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Benign Prostatic Hyperplasia
Prostate Bipolar Enucleation and Resection Versus Open Prostatectomy
Benign prostatic hyperplasia (BPH) is a frequent disease in aging men accompanied by bladder outlet obstruction (BOO). Open prostatectomy (OP) is still considered the first-line treatment for more than 80 ml prostate size.
- Trial name
- NCT05416606
- Testing
- transurethral bipolar enucleation and resection of the prostate, open surgical transvesical prostatectomy
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Helwan University
Myeloma
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.
- Trial name
- NCT04862676
- Testing
- Hyperbaric oxygen
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Rochester
Polycystic Ovarian Syndrome
Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Objective: 1. To investigate the changes in the levels of interleukin-6 and interleukin-8 after 3 months treatment with metformin alone and combination of metformin and pioglitazone in patients with polycystic ovarian syndrome…
- Trial name
- NCT03117517
- Testing
- Metformin, Metformin, Pioglitazone
- Where
- Pakistan
- Volunteers
- 106 people
- Sponsor
- Khyber Medical University Peshawar
Knee Osteoarthritis
Platelet-rich Plasma and Synovial Cytokines in Knee Osteoarthritis
A prospective study was performed on 90 patients were included and categorized into mild (30 cases, moderate (30 cases) and severe (30 cases) knee OA. Three intra-articular (I.A) injections of PRP, 2 weeks a part, were received.
- Trial name
- NCT04754685
- Testing
- Intra-articular injection of platelet-rich plasma
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- South Valley University
Intensive Care Units, ARDS, Human
Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections
Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom…
- Conditions
- Intensive Care Units, ARDS, Human, Covid19
- Trial name
- CovidEP (NCT04751643)
- Testing
- Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3), Usual treatments in intensive care unit according to the current state of knowledge
- Where
- 8 sites in France
- Volunteers
- 21 people
- Sponsor
- Hospices Civils de Lyon
Age Related Macular Degeneration
Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration
In this multi-center study, possible effects of supplement treatment with oral phenolics on plasma CD-163 and progression of dry and wet age-related macular degeneration (AMD) via evaluating the CD163 before and after the…
- Trial name
- NCT05005884
- Testing
- Oral intake of medication
- Where
- Iran
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Multiple Myeloma
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an…
- Trial name
- NCT00006184
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
- Trial name
- RVDD (NCT00724568)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- University of Michigan Rogel Cancer Center
Light Chain Deposition Disease, Refractory Plasma Cell Myeloma
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
This pilot phase I trial studies the side effects and the best dose of giving viral therapy to patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01533194
- Testing
- Diagnostic Laboratory Biomarker Analysis, Wild-type Reovirus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00003402
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00639002
- Testing
- Ruxolitinib 25 mg, Dexamethasone 40 mg
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Incyte Corporation
Interstitial Cystitis
Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating chronic disease of unknown etiology characterized by urgency frequency and suprapubic pain at full bladder.
- Trial name
- NCT03104361
- Testing
- Platelet-Rich Plasma
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Buddhist Tzu Chi General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.